NCT01406691 Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
| NCT ID | NCT01406691 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Stanford University |
| Condition | Delayed Sleep Phase Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2013-12 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 20 participants in total. It began in 2013-12 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Delayed Sleep Phase Disorder (DSPD) is a sleep disruption that commonly occurs in teens and manifests as a difficulty in waking up in the morning, going to sleep early enough at night, and daytime disturbances such as depression, fatigue, and restlessness. The purpose of this study is to determine if brief flashes of light, that are scheduled to occur during sleep, are effective in treating DSPD.
Eligibility Criteria
Inclusion Criteria: * Male or female * Full-time in high school * primary sleep complaint consistent with delayed sleep phase disorder Exclusion Criteria: * sleep only in prone position * currently taking medications specifically for the treatment of a sleep disorder
Contact & Investigator
Frequently Asked Questions
Who can join the NCT01406691 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 19 Years, studying Delayed Sleep Phase Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT01406691 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT01406691 currently recruiting?
Yes, NCT01406691 is actively recruiting participants. Contact the research team at jzeitzer@stanford.edu for enrollment information.
Where is the NCT01406691 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT01406691 clinical trial?
NCT01406691 is sponsored by Stanford University. The trial plans to enroll 20 participants.